mardi 5 juin 2018

Onco Actu du 5 juin 2018 - spécial ASCO

5.5.1 ASCO (général)

ASCO Highlights for Monday, June 4, 2018 [OBR Blog] ASCO (général) - Industriels

ASCO: Merck and its new multibillion-dollar partners hone plans for marketing onslaught [FiercePharma]

ASCO Soundbites, 2018 edition: Comments candid—and not so much—from industry executives [FiercePharma]

Winners And Losers From Cancer Research's Biggest Event [Forbes]

5.5.10 ASCO (hémato)

Seattle Genetics Highlights Additional Analyses from Phase 3 ECHELON-1 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at 2018 ASCO Annual Meeting [Seattle Genetics]

5.5.13 ASCO (divers)

Taking Acid-Reducing Medicine With Aspirin Offers Moderate Benefits in Patients With Barrett’s Esophagus [ASCO]

Combining heartburn drugs and aspirin could help prevent oesophageal cancer in people at high risk [Cancer Research UK]

Aspirin 'helps block tumour formation' [BBC News]

Taking aspirin with acid reducers can slow advance of esophogeal cancer [The Guardian]

5.5.16 ASCO (médecine de précision)

NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies [NCI] ASCO (médecine de précision-sein)

How a U.S. postal stamp helped fund a pivotal study on breast cancer [STAT]

Breast cancer test 'reduces need for chemotherapy' [NHS Choices]

Many Women With Breast Cancer Can Now Skip Chemo, According to a New Study [Vogue]

A big question answered about treating early-stage breast cancer [Washington Post]

5.5.17 ASCO (pancréas)

Chemoradiotherapy before surgery may extend lives of pancreatic cancer patients [Cancer Research UK]

Chemo combo could help pancreatic cancer patients live longer after surgery [Cancer Research UK]

Chemotherapy Regimen Extends Life by Nearly Twenty Months for People With Pancreatic Cancer [ASCO]

Pre-Operative Chemotherapy With Radiation May Help People With Pancreatic Cancer Live Longer [ASCO]

Chemotherapy before surgery could extend pancreatic cancer patients' lives [The Guardian]

5.5.2 ASCO (sein)

ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it? [FiercePharma]

Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting [Puma]

Are the clinical trial results for breast cancer drug taselisib ‘incredibly exciting’ or ‘disappointing’? [HealthNewsReview]

5.5.3 ASCO (prostate)

Lynparza in combination with abiraterone delayed disease progression in metastatic castration-resistant prostate cancer [AstraZeneca] ASCO (immunothérapies-poumon)

ASCO: Merck's solo Keytruda wins again, but might just leave room for competition [FiercePharma]

ASCO: Merck shows Roche up with big survival numbers in squamous lung cancer [FiercePharma]

ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it? [FiercePharma]

Opdivo Plus Chemotherapy Showed Improved Progression-Free Survival Versus Chemotherapy in First-Line Lung Cancer Patients with PD-L1 <1%, in CheckMate -227 Study to Be Presented at ASCO 2018 [BMS]

Merck’s KEYTRUDA® (pembrolizumab) Showed Promising Anti-Tumor Activity in Patients with Advanced Small Cell Lung Cancer (SCLC) in Phase 2 KEYNOTE-158 Study [Merck]

#ASCO18: Bristol-Myers takes another stab at a positive impression for CheckMate-227 [EndPoints] ASCO (immunothérapies-CAR-T, thérapies cellulaires)

Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors [Gilead]

Kite Announces New Data Analyses for CAR T Therapy in Patients with Blood Cancers at the 2018 American Society of Clinical Oncology Meeting [Gilead]

New approach to immunotherapy leads to complete response in breast cancer patient unresponsive to other treatments [NCI]

Therapy Made From Patient's Immune System Shows Promise For Advanced Breast Cancer [NPR]

Doctors hail world first as woman’s advanced breast cancer is eradicated [The Guardian] ASCO (immunothérapies-mélanome)

Opdivo (nivolumab) 3 mg/kg Demonstrates Sustained, Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) 10 mg/kg for Broad Range of Patients with Resected Stage III or IV Melanoma [BMS]

Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Long-Term Survival Benefit Based on Four and Five Years of Follow-Up from Two Pivotal Studies in Advanced Melanoma [Merck]

Merck's Keytruda shows promise in treating advanced melanoma [Reuters]

5.5.5 ASCO (gastro-intestinal)

Heated Abdominal Chemotherapy Not Beneficial in Patients With Advanced Colorectal Cancer [ASCO]

5.5.8 ASCO (poumon)

Dacomitinib Shows More than Seven-Month Improvement in Overall Survival Compared to an Established Therapy in Advanced NSCLC with EGFR-Activating Mutations [Pfizer]

5.5.9 ASCO (autres organes)

Exelixis Announces Results from Sub-Group Analyses of the Phase 3 Pivotal CELESTIAL Trial of Cabozantinib for Advanced Hepatocellular Carcinoma Presented at ASCO 2018 [Exelixis]